Kymab strengthens management team with two senior appointments

UK-based monoclonal antibody biopharmaceutical company Kymab has announced the appointment of Steve Arkinstall as Chief Scientific Officer and Nigel Clark as Vice President and Head of Business Development.

Mr Arkinstall brings overs 25 years’ experience across biopharmaceutical research and development, having worked across several disease areas and specialising in drug target validation, R&D strategic design, antibody discovery and protein engineering. He joins Kymab from Merck Serono, where over his 16 year career he has held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of Global Technologies and External Innovation.

Allan Bradley, Founder and previously Chief Scientific Officer, will continue as an essential member on the Executive Leadership team.  He will serve as Chief Technology Officer driving further advances in Kymab’s proprietary technology platforms, strategic thinking in human population genetics and establishing a vaccine discovery capability. In addition, Mr Bradley will continue to serve as a member of the Board of Directors for Kymab.